Pharming Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PHARMING
PHARMING has one approved drug.
There is one US patent protecting PHARMING drugs.
Summary for Pharming
| US Patents: | 1 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Pharming
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharming | JOENJA | leniolisib phosphate | TABLET;ORAL | 217759-001 | Mar 24, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Pharming | JOENJA | leniolisib phosphate | TABLET;ORAL | 217759-001 | Mar 24, 2023 | RX | Yes | Yes | 8,653,092 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Pharming | JOENJA | leniolisib phosphate | TABLET;ORAL | 217759-001 | Mar 24, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Pharming Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Argentina | 115927 | ⤷ Start Trial |
| South Korea | 101560066 | ⤷ Start Trial |
| Brazil | 112013000275 | ⤷ Start Trial |
| Chile | 2013000033 | ⤷ Start Trial |
| Taiwan | 201206930 | ⤷ Start Trial |
| China | 102971317 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pharming Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2590974 | CA 2026 00029 | Denmark | ⤷ Start Trial | PRODUCT NAME: LENIOLISIB, EVENTUELT I FORM AF ET N-OXID ELLER FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT LENIOLISIBPHOSPHAT.; REG. NO/DATE: EU/1/26/2034 20260521 |
| 2590974 | 301386 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LENIOLISIB, DESGEWENST IN DE VORM VAN EEN N-OXIDE OF FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN, IN HET BIJZONDER LENIOLISIBFOSFAAT; REGISTRATION NO/DATE: EU/1/26/2034 20260521 |
| 2590974 | PA2026527 | Lithuania | ⤷ Start Trial | PRODUCT NAME: JOENJA - LENIOLISIBAS; REGISTRATION NO/DATE: EU/1/26/2034 20260521 |
| 2590974 | 2026C/725 | Belgium | ⤷ Start Trial | PRODUCT NAME: LENIOLISIB, DESGEWENST IN DE VORM VAN EEN N-OXIDE OF FARMACEUTISCH AANVAARDBAARZOUT ERVAN, IN HET BIJZONDER LENIOLISIBFOSFAAT; AUTHORISATION NUMBER AND DATE: EU/1/2026/2034 20260521 |
| 2590974 | C20265013 | Finland | ⤷ Start Trial | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
